Phase II Study of Rituximab in Patients With Immune Thrombocytopenic Purpura

Completed · Phase 2

Conditions studied: Purpura, Thrombocytopenic, Idiopathic

In brief

OBJECTIVES: I. Determine the response rate and response duration to rituximab in patients with immune thrombocytopenic purpura. II. Evaluate the toxicity associated with this treatment regimen in these patients. III. Evaluate the alteration in antiplatelet antibody with this treatment regimen in these patients.

Key facts

Study ID

NCT00005652

Run by

University of Alabama at Birmingham

People needed

20

Starts

2000-12-01

Last updated by the study team

2008-09-09

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• University of Alabama Comprehensive Cancer Center — Birmingham, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.